Shorter treatment duration for selected patients with multidrug-resistant tuberculosis

Leung E.C.C., Yew W.W., Leung C.C., Leung W.M., Tam C.M.

Source: Eur Respir J 2011; 37: 227-230

Journal Issue: July

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Leung E.C.C., Yew W.W., Leung C.C., Leung W.M., Tam C.M.. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur Respir J 2011; 37: 227-230

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019 Year: 2020
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Duration of hospitalization of patients treated for tuberculosis Source: Annual Congress 2010 - Global tuberculosis control Year: 2010
Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated Source: Eur Respir J , 49 (3) 1700081; DOI: 10.1183/13993003.00081-2017 Year: 2017
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico Source: Eur Respir J, 51 (3) 1702267; 10.1183/13993003.02267-2017 Year: 2018
Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis Source: Eur Respir J 2016; 48: 1503-1507 Year: 2016
Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700228; 10.1183/13993003.00228-2017 Year: 2017
Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700463; 10.1183/13993003.00463-2017 Year: 2017
Long-term results of multidrug-resistant tuberculosis treatment. Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003
Reducing loss to follow-up during treatment for drug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1802268; 10.1183/13993003.02268-2018 Year: 2019
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015